Quantcast
Home > Quotes > AERI
x
AERI

Aerie Pharmaceuticals, Inc. Common Stock (AERI) Quote & Summary Data

$56.24
*  
0.87
1.57%
Get AERI Alerts
*Delayed - data as of Oct. 15, 2018  -  Find a broker to begin trading AERI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AERI After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 53.30 / $ 60.60
Today's High / Low
$ 57.04 / $ 54.88
Share Volume
442,813
50 Day Avg. Daily Volume
437,109
Previous Close
$ 55.37
52 Week High / Low
$ 74.75 / $ 47.055
Market Cap
2,543,299,509
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
442,813
50 Day Avg. Daily Volume:
437,109

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -4.94

Trading Range

The current last sale of $56.24 is 19.52% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 57.04 $ 74.75
 Low: $ 54.88 $ 47.055

Company Description (as filed with the SEC)

We are an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye. Our strategy is to commercialize Rhopressa┬«, approved by the FDA on December 18, 2017, in North American markets and advance our product candidate, RoclatanTM, to regulatory approval. We are in the process of hiring a commercial team that will include approximately 100 sales representatives to target approximately 12,000 high prescribing eye-care professionals throughout the United States. This sales force will initially be responsible for sales of Rhopressa┬«, and will also be responsible for sales of RoclatanTM, if approved. Our strategy also includes developing our business outside of North America, including obtaining regulatory approval in Europe and Japan on our own for Rhopressa┬« and RoclatanTM.  ... More ...  


Risk Grade

Where does AERI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 55.26
Open Date:
Oct. 15, 2018
Close Price:
$ 56.24
Close Date:
Oct. 15, 2018

Consensus Recommendation

Analyst Info